AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00387673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
Study NCT00387673 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
Study NCT01722942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD implantation
Description: ventricular ICD implantation
Study NCT01722942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone hydrochloride
Description: amiodarone prescription
Study NCT02492854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Single-Use Negative Pressure Dressings
Description: Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
Study NCT02492854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Gauze Dressings
Description: Current standard-of-care dressings used to cover surgical wounds post-operatively.
Study NCT04492579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle-UHT donor human milk supplementation
Description: Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born >36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
Study NCT02635048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini Percutaneous Nephrolithotomy
Description: patients undergo PNCL with 18Fr nephrostomy tract
Study NCT02635048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy
Description: patients undergo PNCL with 24Fr nephrostomy tract
Study NCT01981733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
Study NCT02578979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
Study NCT02578979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holter
Description: Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
Study NCT03027648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of levonorgestrel-releasing intrauterine system
Description: All the patients accepted treatment of levonorgestrel-releasing intrauterine system
Study NCT02216773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency assisted liver partition with portal vein ligation (RALPP)
Study NCT02216773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal vein embolization (PVE)
Study NCT00630565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
Study NCT01085838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
Study NCT02426788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Description: Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
Study NCT03356379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
Study NCT03356379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
Study NCT03996850 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo SPECT/CT
Study NCT03996850 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03996850 — intervention group
Intervention type: PROCEDURE
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT03996850 — intervention group
Intervention type: RADIATION
Intervention: Technetium Tc-99m Sestamibi
Description: Given IV
Study NCT00630565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
Study NCT00630565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow transplantation
Description: Day 0 infusion of bone marrow cells
Study NCT00630565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation
Description: Stem cell infusion (>48 hours after the last dose of cyclophosphamide)
Study NCT00630565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infusion of peripheral blood stem cells
Study NCT00630565 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 165 cGy/dose given twice a day on days -7 through -4.
Study NCT01046253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg Delayed-Release Capsules
Study NCT01046253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg Delayed-Release Capsule
Study NCT03061565 — intervention group
Intervention type: DRUG
Intervention: erythropoietin
Description: Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Study NCT03061565 — intervention group
Intervention type: DRUG
Intervention: Placebos
Description: Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Study NCT01751555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen:TDF+3TC+EFV
Description: TDF+3TC+EFV for HIV/HBV co-infection
Study NCT03069092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
Study NCT03069092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
Study NCT03069092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise
Description: Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
Study NCT02158884 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IDEO brace
Description: All participants will receive the IDEO brace.
Study NCT04540874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416
Study NCT04540874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03031964 — intervention group
Intervention type: DEVICE
Intervention: revision multihole acetabular cup
Description: post market study of multi hole revision acetabular cup
Study NCT01134146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
Study NCT02428465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purposeful Parenting
Description: Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
Study NCT03189784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement techniques
Description: patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
Study NCT03076255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation
Study NCT03076255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Given thermoplastic mask
Study NCT03076255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Given MID
Study NCT03076255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT imaging
Study NCT02440633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-OPS-2071
Description: Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
Study NCT03785210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vancomycin
Description: 125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
Study NCT01189370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week.
Study NCT04098393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan 3.2 mg/kg/day
Description: Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
Study NCT01957436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
Study NCT01957436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
Study NCT01957436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
Study NCT02595463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
Study NCT02595463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
Study NCT00646815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone (genotropin)
Description: Dosage regulation will follow the local recommendations of GHD treatment
Study NCT05976269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
Study NCT05976269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin L-proline
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipragliflozin L-proline
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02794792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral
Study NCT00579280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine SR
Description: flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
Study NCT00579280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: divalproex sodium ER
Description: Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
Study NCT04447391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise program
Description: Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet
Study NCT04447391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 300 kcal deficit diet only
Study NCT00579280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02482480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
Study NCT02482480 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Dietary and general recommendations
Study NCT03625375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
Study NCT01160081 — intervention group
Intervention type: OTHER
Intervention: Serum sample
Description: Serum samples collected
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with saline water and occluded with Tegaderm
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with saline water
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with Ethyl alcohol solution
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Visonac left on the skin for 24 hours in facial area one
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Visonac wiped off after one hour
Study NCT01160848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Visonac left on the skin 24 hours in facial area two
Study NCT02379182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard clinical care
Description: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
Study NCT02379182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard clinical care
Description: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
Study NCT02379182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation at sensory level
Description: The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
Study NCT02379182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation at motor level
Description: The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
Study NCT03848403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT00956566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: dietary counseling, group teaching